Search

Displaying results 471 - 480 of 2507 in total
  1. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  2. Drug

    Polyethylene glycol 400

    go.drugbank.com/drugs/DB11077
    ApprovedInvestigational

    Polyethylene glycols (PEGs) are products made of condensed ethylene oxide and water that can contain various derivatives and have various functions. Because many PEG types are hydrophilic, they are favorably used as enhancers of penetrat...

    Mixtures: Hydration PF, Systane Hydration PF Preservative FreeCategories: P-glycoprotein inhibitors
  3. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    The main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].

  4. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    Antineoplastic effects and potential uses of somatostatin on various tumours, including pituitary adenomas, GEP-NETs, paragangliomas, carcinoids, breast cancers, malignant lymphoma and small-cell lung

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  6. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]

  7. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  8. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. … [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).

  9. Drug

    PF-03758309

    go.drugbank.com/drugs/DB11775
    Investigational

    PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.

    Salts: Pf 03758309 Hydrochloride
  10. Drug

    PB-722

    go.drugbank.com/drugs/DB18447
    Experimental

    PB-722 is a long-acting glucagon receptor agonist.[L48260]